3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
2
Thymoma
2
Endometrial Neoplasms
2
Uterine Prolapse
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Prostatic Diseases
1
Precancerous Conditions
1
Pelvic Organ Prolapse
1
Ovarian Neoplasms
1
Obesity, Morbid
1
Myasthenia Gravis
1
Menstruation Disturbances
1
Mediastinal Neoplasms
1
Leiomyoma
1
Hernia, Ventral
1
Hernia, Inguinal
1
Genital Diseases, Female
1
Endometriosis
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Adenomyosis
1
Interventions
pembrolizumab
24
Carboplatin
21
Paclitaxel
20
olaparib
19
Magnetic Resonance Spectroscopy
14
Bevacizumab
14
Cyclophosphamide
12
Specimen Handling
11
Nivolumab
11
Gemcitabine
11
Taxes
10
niraparib
8
Cisplatin
8
Biopsy
8
liposomal doxorubicin
7
fludarabine
7
Surveys and Questionnaires
6
Immunoglobulin G
6
Doxorubicin
6
Disulfides
6
durvalumab
5
palbociclib
4
oregovomab
4
X-Rays
4
Ipilimumab
4
mirvetuximab soravtansine
3
ipatasertib
3
defactinib
3
cediranib
3
atezolizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Ovarian Neoplasms
×
Robotic Surgical Procedures
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled